Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity. by Ching, L. M. et al.
Brtish Joumal of Cancer (1998) 78(3). 336-343
c 1998 Cancer Research Campaign
Interaction of thalidomide, phthalimide analogues of
thalidomide and pentoxifylline with the anti-tumour
agent 5,6-dimethylxanthenone-4-acetic acid:
concomitant reduction of serum tumour necrosis
factor-alpha and enhancement of anti-tumour activity
L-M Ching, WL Browne, R Tchernegovski, T Gregory, BC Baguley and BD Palmer
Auckland Cancer Society Research Centre. University of Auckland School of Medicine. Auckland. New Zealand
Summary DMXAA (5,6-dimethylxanthenone-4-acetic acid), a novel anti-tumour agent currently undergoing clinical evaluation. appears to
mediate its anti-tumour effects through immune modulation and the production of the cytokine tumour necrosis factor-a (TNF). Our previous
studies have shown that thalidomide, a potent inhibitor of TNF biosynthesis that has numerous biological effects, including inhibition of tumour
angiogenesis. unexpectedly augments the anti-tumour response in mice to DMXAA. We show here that thalidomide (100 mg kg-) has no
effect when administered with inactive doses of DMXAA, and that it must be given simultaneously with an active dose of DMXAA to have its
maximum potentiating effect on the growth of the munne Colon 38 adenocarcinoma. To address the issue of whether inhibition of serum TNF
production is important for potentiation of anti-tumour activity, we have tested three potent analogues of thalidomide. All three analogues.
when co-administered with DMXAA to mice at doses lower than those used with thalidomide, inhibited TNF production and were effective in
potentiating the anti-tumour activity of DMXAA against transplanted Colon 38 tumours. One of the analogues, N-phenethyltetrafluorophthalimide.
was 1000-fold more potent than thalidomide and at a dose of 0.1 mg kg-' in combination with DMXAA (30 mg kg-') cured 1000 of mice.
compared with 670o for the group treated with DMXAA alone. We also tested pentoxifylline and found it to suppress TNF production in
response to DMXAA and to potentiate the anti-tumour effect of DMXAA. The results are compatible with the hypothesis that pharmacological
reduction of serum TNF levels might benefit the anti-tumour effects of DMXAA and suggest new strategies for therapy using this agent.
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Colon 38
We hax e dexeloped a series of xanthenone analogues of the
drug flax one acetic acid (FAA that are highly actixe against
transplantable murine tumours w-ith an established Xasculature
(Rex-castle et al. 1989. 1991). The most potent of these. 5.6-
dimethN-lxanthenone4-acetic acid (DMXAA). is now- in phase I
clinical trials in New Zealand and the UK. In mice. DNIXAA is
12-fold more potent than FAA and induces a higher percentage of
cures acainst the Colon 38 carcinoma (Rexwcastle et al. 1991).
DNIXAA and FAA share a mechanism of action that is different
from that of conventional direct cvtotoxic anti-cancer drugs. Both
appear to actix-ate. through host and tumour cell components. a
complex series of responses involving shutdown of tumour blood
floxw (Z"-i et al. 1989. 1994). stimulation of immune responses
(Ching and Bagulev. 1987: Ching et al. 1991) and elimination of
the tumour.
NManv of the biolo2ical actix-ities of DMNXAA and FAA have
been attributed to their abilitv to induce cxtokines. in particular
TNF and the interferons (Mace et al. 1990: Futami et al. 1992:
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Philpott et al. 1995). w-hich have peak serum concentrations 2-3 h
after DMNIXAA administration. The early vascular effects appear to
be mediated by tumour necrosis factor-a (TNT) as antibodies to
T-NF ablate FAA-induced tumour x-ascular collapse (Mahadex an et
al. 1990). DMXAA induces hiaherlexels of serum TNF than FAA.
and the anti-tumour response correlates well w-ith TNF production
within a series of DMXAA analoaues (Philpott et al. 1995).
As an approach to inx estigating the role ofTNF induction in the
anti-tumour action of DNMXAA. wxe co-administered thalidomide
wxith DMXAA to mice x ith subcutaneous Colon 38 tumours
(Ching, et al. 1995). Thalidomide. best knowxn for its sedatixe and
teratogenic effects (Fabro et al. 1967). has receixed attention in
recent -ears as a selectixe inhibitor of TNT production Sampaio
et al. 1991 ). apparently acting, by increasing the rate ofdegradation
ofTNT m_RNA (Moreira et al. 1993). We haxe shoxwn that thalido-
mide inhibits DMXAA-induced serum TNF lexels. but. unexpect-
edly. potentiates the anti-tumour response (Ching et al. 1995).
While these results appear to argue against a role for TNF in the
anti-tumour action of D.MXA. they indicate a noxvel approach to
augmenting the anti-tumour action ofDMXAA.
Recently. sexeral phthalimide-derixved analogues ofthalidomide
hax-e been described that are more potent than thalidomide in
modulating TNF production in cells stimulated with a phorbol
ester (Sasaki et al. 1995). The druc pentoxif-lline is also knoxxn
to suppress TNF production in response to administration of
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Figure 1 Structures of thalidomide. PP. PEP. PEFP. pentoxifyiline and DMXAA
lipopolx-sacchande (Noel et al. 1990). In this report. w-e have
further investioated the interaction of thalidomide and DMXAA
and has-e investigated a series of three phthalimide derivatives. as
ell as pentoxif lline. to determine whether they also suppress
TNF production in response to DMXAA and whether thev
potentiate DMXAA-induced anti-tumour effects.
MATERIALS AND METHODS
Materials
DMXAA. svnthesized in this laboratorv by Dr GA Rew-castle
(Rewcastle et al. 1991). w-as dissolved in 5%z7c sodium bicarbonate
and xwas injected intraperitoneallv (i.p.) in a volume of 0.01 ml g-'
bodv weight. (->-Thalidomide. N-phenylphthalimide (PP).
N-phenethylphthalimide (PEP). and N-phenethyltetrafluorophthal-
imide (PEFP) (chemical structures in Figure 1) were synthesized
according to published methods (Casini and Ferappi. 1964: Sasaki
et al. 1995). dissolved in dimethyl sulphoxide and injected at
2.5 I1 g-' body wei5ht. Clinical formulations of pentoxifylline
(Trental. Hoeschst. Frankfurt. Germany) were diluted in saline to
required concentrations for i.p. injections.
Measurement of anti-tumour activity
All experiments were carried out in 8- to 12-vveek-old C57B1/6 x
DBAI2 F (BDF, mice bred in the laboratorx animal facilitv and
treated according to institutional auidelines. Fragments of Colon
38 tumour (1 mm¼) were implanted subcutaneously in the flank of
anaesthetized (sodium pentobarbital. 90mr kg-' i.p.) animals.
Experiments were carried out on tumours approximately 4-5 mm
in diameter. grenerally 10 days after implantation. Tumour-bearing,
mice (at least five per group) were injected w-ith drugs and the
tumours measured with callipers two or three times per week
thereafter. Tumour volumes were measured as 0.52 a: x b. where
a and b are the minor and major axes ofthe tumour. The arithmetic
mean and standard error of the means A-ere calculated for each
time point. including animals having zero measured tumour
volume. and expressed as a fraction of the pretreatment volume.
Growth delav was determined as the difference in the number of
days required for the control and treated tumours to reach four
times the pretreatment xolume. Statistical tests w-ere carried out
using SigmaStat (Jandel Scientific. San Rafael. CA. USA). Mice
cured of tumours were kept for at least 3 months to ensure that
tumours did not regrow.
Histological examination of tumour sections
Mice w-ith Colon 38 tumours w-ere treated with DMXAA (single
dose. 24 mg kg-'). either alone or w-ith thalidomide (100 mg kg-').
Tumours were excised 1-10 dayvs after treatment. fixed overnight
in 10% formalin. Fixed tumours were then embedded in paraffin
wax and sections were stained w-ith haematoxvlin and eosin. The
section across the major diameter of the tumour w-as examined on
a grid marked at 0.4-mm intervals and scored for the percentage
area ofviable tissue as previously described (Bagulev et al. 1989).
Determination of serum TNF
Mice were anaesthetized using halothane and wA-ere bled from the
ocular sinus at indicated times after treatment. Blood w as allowed
to clot ovemirht on ice and the serum collected by centrifu2ation
(2000 g. 30 min) and stored at -20 C until it was assayed for TNF
activity. using the standard L929 cvtotoxicitx assay as described
(Philpott et al. 1995). L929 cells (3 x 10-) were allowed to adhere
oxerniht to the bottom of flat-bottomed 96- ell plates.
Actinomycin D (final concentration 8 ,gr ml-') was then added to
the wells followed by serial dilutions of the serum to be assayed.
Killinc of the L929 cells was assessed after 24 h by a colorimetric
assay using 3-(4.5-dimethvl-2-thiazoly l)-2.5-dipheny-l-2H-tetra-
zolium bromide. One unit ofTNF A as defined as that reducing cell
staining in this assay by 50%. and corresponded to the activitx
obtained with 10-" ofpunrfied murine TNF protein.
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Figure 2 Potentiation of DMXAA-induced tumour growth inhibition by thalidomide. Growth of Colon 38 tumours in mice with no treatment (-); with DMXAA
15 mg kg-' (A): with 20 mg kg-' DMXAA (B): with 25 mg kg-' DMXAA (C): with 30 mg kg-' DMXAA (D) either alone (open symbols) or together with thalidomide
at 100 mg kg-' (closed symbols). Veriical bars indicate s.e.m. In some cases. s.e.m. values are smaller than the size of the symbol
RESULTS
Potentiation of anti-tumour activity of DMXAA by
thalidomide
Thalidomide potentiates the anti-tumour response of DMXAA at
its optimal therapeutic dose of 30 mg kg-I when administered
simultaneously (Ching et al. 1995). To investigate whether thalido-
mide potentiated suboptimal doses of DMXAA. mice with Colon
38 tumours were treated with thalidomide (100 mg kg-') and a
range of doses of DMXAA from 15 mg, kg-I to the maximal-
tolerated dose (MTD) of 30 mg kg-'. Tumour growth delays and
cure rates appeared to be increased by thalidomide after DMXAA
doses of 25 and 20 mc kg-' but not after a dose of 15 mg kg-I
(Figure 2 and Table 1). How-ever. the differences between groups
were not statistically significant. analysis beina complicated by the
percentage of cures in each group. We also examined the effect of
changing the timinc ofadministration. using DMXAA at its MTD.
W'hile ggrowth delays were potentiated by thalidomide given simul-
taneously wvith DMXAA. in agreement w-ith previous results
(Ching et al. 1995). they were not significantly increased when
thalidomide w-as given 1 day before. or 1. 2 or 3 davs after
DMXAA (Figure 3 and Table 1).
Histology of tumour regrowth after treatment with
DMXAA and thalidomide
The histology of tumours treated with DMXAA either alone or in
combination with thalidomide (100 mr kg-') was examined by
measuring the proportion ofviable tissue in tumour sections taken at
different times after treatment. A suboptimal dose of DMXAA w as
used (24 mg kg-' ) to permit a significant amount of viable tissue to
be measured. Extensive haemorrhagic necrosis w-as evident in both
treatment groups when measured after 24 h. However. pockets of
viable tissue that were visible in tumours treated with DMXAA
were less evident than those in tumours treated w-ith the combina-
tion. and the amount of viable tissue in tumours treated with the
combination w-as lower than that in tumours treated with DMXAA
alone (Figure 4. While the proportion ofregenerating viable tumour
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Table 1 Cure rates and growthldelays of tumours treated with DMXAA and thalidomide time dependence (data from Figures 2 and 3)
Dose Time between DMXAA Growth delay (days) Percentag cures
(mg kg-') and thalidomide (h)
DMXAA DMXAA+ DMXAA DMXAA+
thalidomide thalidomide
15 0 6 6 0 28
20 0 10 15 36 48
25 0 15 25 60 80
30 0 20 - 67 100
30 -24 17 83
30 +24 9 75
30 +48 16 40
30 +72 23 56
c t
100,
a)
.0
C 10-1 .5
c;
0
0 a.
1-
C- -- --C
0 2 4 6 8
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I
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Figure 3 Effect of time of administration of thalidomide in relation to that of
DMXAA. Growth of Colon 38 tumours in mice with no treatment (0), with
30 mg kg- DMXAA (_ ), with thalidomide (100 mg kg-') given at the same
time as DMXAA (hexagons), one day before (*), one day after (=). 2 days
)and 3 days afterC)
tissue increased steadilv w-ith time in the animals treated with
DMXAA only. the proportion in tumours from mice treated with the
combination increased only for 3 days after treatment (Figure 4).
10 12
Figure 4 Measured percentages of viable Colon 38 tumour in tissue
secfions taken at various times after administration of DMXAA (24 mg kg-')
either alone (0) or together with thalidomide (100 mg kg-) (- )
no effect was found on the take-rate or growth of the Colon 38
tumour. Rather. the rate of growth was slightly accelerated bv
thalidomide treatment. and the tumours became palpable sooner in
the treated amnmals (Figure 5). Thus there wias no evidence for
inhibition of neoxascularization. and thus of tumour growth and
development. usinc thalidomide alone at doses of 100 mg kg-
Effect of thalidomide alone on tumour development
and growth
Thalidomide is known to inhibit anciooenesis (DlAmato et al.
1994). and angiogenesis antagonists can increase the anti-tumour
response to radiation and chemotherapy through inhibition of
tumour neovascularization (Teicher et al. 1993: D'Amato et al.
1994). To test the hypothesis that thalidomide. administered alone.
was affecting the growth of Colon 38 tumours. mice w-ere treated
either w-ith a single dose or ,iith multiple doses of thalidomide
(100 mg kg- per injection). No inhibition of tumour growth was
observed in mice treated w-ith a single injection of thalidomide
(100 mg kg-'). or ith injections three times Aeekly for the dura-
tion of the experiment (1100 mg kg- per injection). Furthermore.
Awhen thalidomide alone A as gixven at the time of tumour implanta-
tion and three times Aeeklv thereafter (100 mg kg-' per injection).
Ability of analogues of thalidomide to inhibit serum
TNF production and potentiate the anti-tumour action
of DMXAA
A series of simple phthalimide derivatives that are more potent
than thalidomide in modulating serum TNF production has been
reported (Sasaki et al. 1995). We synthesized three of these more
dose-potent derivatives (PP. PEP and PEFP) and compared their
abilitx v ith thalidomide to suppress DMLXAA-induced serum TNF
production and to potentiate anti-tumour action. PEFP w-as the
most toxic of the three compounds. inducing deaths at 3 days at
doses above 50 mg kg-'. whereas the other two derivatives were
A-ell tolerated at 100 mg kg-1. In comparison. thalidomide was
well tolerated up to 250 mg kg-I in mice (Ching et al. 1995).
Comparisons of inhibition of serum TNF production w-ere
carried out using a dose of DMXAA (50 mg kg-') that Awas optimal
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Figure 5 Effect of thalidomide on tumour establishment. Mice (12 per
group) were implanted with Colon 38 fragments and either untreated (open
bars) or treated with thalidomide (100 mg kg-') at thetime of implantation and
thrice weekly for the duration of the experiment (shaded bars). Mice were
checked for palpable tumours (greater than 2 x 2 mm2) after implantation
for the TNF response 2 h after treatment but that caused no toxic
effects at the time of the assay (Philpott et al. 1995). Each of the
phthalimide derixatixves inhibited DMXAA-induced serum TNF
production (Figure 6). PEP. PP and PEFP %vere more dose-potent
than thalidomide and. "-hen administered at a dose of 0.1 mg kg-.
inhibited TNF lexels to 58. 18 and 8.5%k. respectively. of DMXVAA
controls (Figure 6). They xx-ere thus more potent than thalidomide.
"-hich was actix-e at a dose of 0.3 mg kg-. In contrast to thalido-
mide. none of the phthalimide derivatixves caused sedation (results
not sho"-n).
We next compared the ability of the phthalimide analogues at a
dose (10 mg kg-') that suppressed serum TNF production (Ficure
6) to potentiate the anti-tumour response of DMXAA (30mgr
kg- ). Combination of DMXAA A-ith PEFP and PP produced cures
against the Colon 38 tumour in 100% of the mice (Ficure 7). A-hile
combination with PEP caxve cures in 75%7e ofthe mice and extended
the growth delay to oxer 60 days. At this dose. thalidomide "-as the
least actix-e of the four agents. Thus. all three phthalimide derixa-
tixes appeared to be more potent than thalidomide in potentiating
the anti-tumour actix itv of DMXAA.
As PEFP "-as the most actix-e in reducing serum TNF lexels
Ficure 6). A e tested this compound at low er doses for potentiation
of the anti-tumour action. PEFP A.1 mg kg- in combination "-ith
DNIX.AA (30 mc kg-1) induced cures in 100%' of the animals
(Figrure 8) and thus >-as at least 1000-fold more potent than
thalidomide. Ahich required a dose of 100 mc ko' in combination
wvith DNMXAA for a 100% cure rate (Table 1). PEFP had no anti-
tumour effects on its own at its maximal-tolerated dose (Figure 8).
and this >-as also the case for PEP and PP (100 mg k-': data
not shox-n).
Inhibition of serum TNF production and potentiation of
DMXAA anti-tumour action by pentoxifylline
The studies w-ith the phthalimide derixatixes extended our
prexious demonstration that inhibition of serum DMXAA-
induced TNF production xxas concomitant x-ith the potentiation
of DMXAA anti-tumour action (Figures 6 and 7). We therefore
examined pentoxifylline. a structurallv unrelated inhibitor
(Figyure 1). w-hich. like thalidomide. inhibits TNF production in
response to lipopolx-saccharide (Noel et al. 1990). We found that
co-administration of pentoxifylline at doses of 12.5-100 mg kg-1
reduced DMXAA-induced serum T'NF bv 50-805 (data not
shown). Co-administration of pentoxifxlline (50 mg kgY-
increased the growth delav induced by DNIXAA (30 mg kg- )
from 19 to more than 40 dayvs (Figure 9A) and increased the cure
rate from 64A' to 82%. but these differences were not statistically
si2nificant. Co-administration of DNIXAA w-ith pentoxifylline
(100 mg kgx- ) induced complete tumour regressions in 100% of
the mice (Figure9B
DISCUSSION
W'e have previously demonstrated that thalidomide. while
reducina DNIXAA-induced increases in serum TNF. potentiates
the anti-tumour response of DNIXAA (Ching et al. 1995). We have
shown similar effects to thalidomide firstly for three derivatives of
phthalimide structurally related to thalidomide (Sasaki et al. 1995)
and secondly for pentoxifA-lline. w-hich differs from thalidomide in
both structure and mechanism of TNT inhibition (Han et al. 1990:
Sampaio et al. 1991). The augmentation of anti-tumour activitv bv
these drugs (Figures 7-9)is difficult to assess statisticallv because
DMXAA alone induces a percentage of cures. and a large number
of animals are therefore required to achiex-e statisticall1 sienificant
differences in cure rates. How-ever. taken together. the results are
consistent w-ith the conclusion that the potentiation of the anti-
tumour action of DMNXAA is associated with the common property
of pentoxifylline. thalidomide and the phthalimides to decrease
serum TNF production. Co-administration of agents lowerincy
serum TNF may thus represent an innoxvative strateav for
increasing the anti-tumour efficacy of DMIX.AA. a drug that is
currently in phase I clinical trial.
Thalidomide has a number of pharmacological actions.
includinc the inhibition of angiogenesis (DAmato et al. 1994).
raisin2 the question of whether potentiation of DMXAA actix ity is
mediated by its anti-angiogenic properties. Administered alone.
thalidomide had no inhibitorx effect on the row-th of the Colon 38
tumour (Ching et al. 1995). and repeated dosing did not affect the
development and growxth of the Colon 38 tumour (Fioure 5. A
single dose. administered at the same time as DMXAA (Fiaure 3).
was required for the synergistic effect. and thalidomide did not
affect tumour growth when administered with an ineffective dose
of DMXAA (Figure 2). Inhibition of tumour angiogenesis requires
repeated or continuous application of the angiogenesis antaconist
(D'Amato et al. 1994). and it is likely that higher doses than that
used in these experiments are necessarx for inhibition ofneox ascu-
larization (RJ d'Amato. personal communication). W'hile we have
not ruled out completely that thalidomide may be potentiating the
anti-tumour activitv of DMXAA through inhibition of anaioeen-
esis. it appears more likely that it is acting in some other fashion.
Histoloaical studies indicate that the augmented tumour growth
inhibition of the combined therapy stems from an acute effect
resulting in a greater reduction in tumour cell survival at 24 h and
from a subsequent slower rate of regeneration (Figure 4. These
obserxations suggest that thalidomide minht in some w-ax increase
the actions of the induced cvtokines.
The mechanism bx which thalidomide. the phthalimide derixa-
tixes and pentoxifx lline inhibit serum TNF production is not vet
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Figure 6 Suppression of DMXAA-induced serum TNF actvity by thalidomide and its analogues. Individual mice were treated with DMXAA
(50 mg kg-') alone or together with thalidomide, PP, PEP or PEFP at the indicated doses, or with drug aloe. Sera were collected 2 h later and assayed for TNF
actty. The control actvity for PP and PEP was 3393 units and that for PEFP and thalidomide was 2440 units
understood. In cultured cells. thalidomide can either inhibit or
enhance TNF production. depending on the conditions and the cell
type. TNF production by HL-60 cells in response to phorbol esters
as increased by co-incubation with thalidomide, as well as by the
phthalimide analogues used in this study (Nishimura et al. 1994).
Thalidomide also enhanced TNF svnthesis (in response to
lipopolysaccharide) in THP-1 cells and in human mononuclear
cells enriched for adherent cells. but inhibited TNF svnthesis in
cultures of unfractionated peripheral blood cells (Shannon and
Sandoval. 1996). We do not yet know whether these mechanisms
will apply in vivo or whether other mechanisms are insols ed. We
are currently investigating whether these drugs affect the in vi--o
pharmacokinetics of DMXAA.
The observation that lowering of serum TNF levels is associated
with improving the anti-tumour activity of DMXAA appears to
contradict previous studies that show that antibodies to TNF
inhibit tumour vascular collapse and ameliorate FAA-induced
anti-tumour action (Mahadevan et al. 1990: Pratesi et al. 1990). In
another tumour model. we have shown that antibodies to TNF
partly inhibit the action of DMXAA. consistent with the above
observations (WL Browne et al. manuscript in preparation). In
recent studies. we have shown that TNF is produced in response to
DMXAA in tumour tissue and that co-administration of thalido-
mide. while reducing serum TNF. does not reduce tumour-associ-
ated TNF (WL Browne et al. manuscript in preparation). Further
studies are now in progress to determine the mechanism by which
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Figure 7 Effect of thakdomide and its analogues on DMXAA-induced
tumour growth inhibition. Colon 38 tumours were measured either untreated
(_) or after treatment with DMXAA (30 mg kg-') (0), DMXAA (30mg kg-')
plus thalidornkle (10mg kg-') (), DMXAA plus PEP (10 mg kg-') (=),
DMXAA plus PEFP (10 mg kg-') (A) or DMXAA plus PP (10 mg kg-')
(hexagons)
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Figure 8 Effect of PEFP alone or in combination with DMXAA on tumour
growth. Colon 38 tumours were measured either untreated (0) or after
treatment with PEFP alone (50 mg kg-') (0), DMXAA alone (U), DMXAA
(30 mg kg-') plus PEFP (0.1 mg kg-') (A) or DMXAA (30 mg kg-') plus PEFP
(10 mg kg-') (hexagons)
TNF is produced in tumours and to identify the source of the TNT
in serum. How-ever. we can conclude from the data obtained so far
that the inhibition of serum TNF bv thalidomide and the other
drugs investigated here does not contradict the hypothesis that
TNF mediates the effect of DMXAA in tumours.
In conclusion. we have shown here that pharmacological
modulators of TNT production can be applied to reduce serum
levels of TNF while increasing the anti-tumour effects of
DMXAA. The phthalimide derivatives are more activ-e and potent
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Figure 9 Potentiation of DMXAA-induced tumour growth inhibition by
pentoxify1line. (A) Growth of Colon 38 tumours in mice with no treatment (0).
with pentoxifyfline alone (U), DMXAA (30 mg kg-') (A) or DMXAA together
with pentoxifylline (50 mg kg-') (*). (B) A similar experiment using
pentoxifylline at a dose of 100 mg kg-
than thalidomide and lack the sedatory effects. presumably
through the elimination ofthe Olutarimide substituent ofthe mole-
cule and interaction with the glutamate receptors in the brain. The
co-administration of pharmacological TNF modulators such as
these may lead to improved strategies to exploit the novel biolog-
ical properties ofDMXAA in a clinical situation.
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